Antiviral Drug Development
Scientists in the rapidly evolving field of antiviral therapeutics are continuously researching and developing highly potent and less toxic antiviral drugs for viral infections with a high impact on the world population such as HIV, hepatitis C, and influenza virus. However, only a few drugs have been approved for the treatment of viral infections in humans. This is because, although many compounds have potent antiviral activity in cell culture, only a small fraction of them will become antiviral drugs for human use. Currently, a variety of broad-spectrum antiviral inhibitors, such as allosteric inhibitors, covalent antiviral agents, or antiviral compounds targeting protein-protein interactions have shown great promise for the future treatment.
Combining the expertise of BOC Sciences' experts in medicinal chemistry, computational chemistry and chemical biology, we help you develop novel antiviral drugs at a faster speed. BOC Sciences is an industry expert in the design and development of antiviral drug delivery solutions, and we offer antiviral drug development services with the flexibility and experience to tailor solutions for each project.
Our Capabilities
- API Development
Despite the increasing complexity of small molecule antiviral drugs, BOC Sciences can apply years of proven expertise in API development to enhance the success of your project. We have a wide range of API development capabilities, ranging from route design, to process optimization and full validation support.
- Formulation Development
We adhere to data-driven decision making strategy coupled with years of formulation expertise to meet the therapeutic and delivery needs of antiviral drugs to deliver APIs to their targets.
- Analytical Development
Our wide range of antiviral analytical services include: method development and validation, reference standard identification, testing and release studies, and stability studies.
Figure 1. Targets of antiviral drug therapy. (Chaudhuri, S.; et al. 2018)
Comprehensive Services
At BOC Sciences, our antiviral API services are geared towards process design in QbD to process development in the laboratory, from commercial production to data-based filings, and our analytical and quality assurance teams are committed to providing professional services and comprehensive analytical studies, including method development and validation, process validation, impurity identification and isolation, API and intermediate studies, and API stability testing.
- Reliable and robust API process development and optimization
- Assurance of quality, safety, efficiency and sustainability
BOC Sciences has various facilities, equipment and instrumentation to develop a variety of dosage forms including tablets, capsules, granules, ointments, emulsions, gels, injectables and oral solutions. In addition, we are highly skilled in developing complex dosage forms of antiviral drugs. At BOC Sciences, our experts guide our clients to make smarter formulation choices, reduce the risk of clinical failure, and ensure that your product reaches the clinic quickly through the most efficient route.
With a team of experienced analytical scientists and a full suite of specialized equipment, BOC Sciences has the ability to develop, test, and validate analytical methods for a variety of antiviral drugs to support robust product launches. Our teams can offer comprehensive antiviral drug analysis services, tailored to each stage of development throughout your program.
- Analytical method development and validation
- Existing method validation, testing and transfer
- Elemental analysis and risk assessment
Why Partner with BOC Sciences?
- We apply our years of proven expertise and experience in antiviral drug development to improve the success of your program
- Our continuously updated facilities support a range of antiviral drug analysis and manufacturing services
- BOC Sciences' experienced team of scientists and regulatory staffs are focused on working with our clients to deliver timely and high-quality small molecule antiviral drugs
- Our partnerships with leading experts in emerging technologies allow us to apply innovative solutions to your antiviral drug research programs
Reference
- Chaudhuri, S.; et al. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral research. 2018. S0166354218301803.
※ Please kindly note that our services are for research use only.
